News
Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 drugs ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
12d
TipRanks on MSNEli Lilly’s Stock Dips Amid Earnings Outlook CutEli Lilly & Co has experienced a significant stock price drop of 10.58% over the past week, despite delivering impressive first-quarter results for 2025. The company’s revenue s ...
Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...
A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...
This was the stock's fourth consecutive day of losses.
Eli Lilly (NYSE:LLY) shares trended lower in the premarket on Thursday after the Indiana-based drugmaker lowered its full-year non-GAAP earnings outlook to a level below consensus, despite surging ...
On Thursday morning, BMO Capital's Evan David Seigerman made his move on Eli Lilly. He knocked $110 per share off his price target for a new fair-value assessment of $900 per share, while maintaining ...
Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance ...
Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential ... so on that basis, the stock is very inexpensive. The GLP-1 market continues ...
What is not priced into the stock, though, is the huge potential of orforglipron. That makes Eli Lilly a buy in my book. Geoffrey Seiler has no position in any of the stocks mentioned. The Motley ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results